Competing designs for phase I clinical trials: a review
Authors:
- 10 September 2002
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 21 (18) , 2757-2770
Abstract
Phase I clinical trials are typically small, uncontrolled studies designed to determine a maximum tolerated dose of a drug which will be used in further testing. Two divergent schools have developed in designing phase I clinical trials. The first defines the maximum tolerated dose as a statistic computed from data, and hence it is identified, rather than estimated. The second defines the maximum tolerated dose as a parameter of a monotonic dose–response curve, and hence is estimated. We review techniques from both philosophies. The goal is to present these methods in a single package, to compare them from philosophical and statistical grounds, to hopefully clear up some common misconceptions, and to make a few recommendations. This paper is not a review of simulation studies of these designs, nor does it present any new simulations comparing these designs. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
Funding Information
- National Cancer Institute (R01-CA 87746-01)
This publication has 48 references indexed in Scilit:
- Optimal Bayesian-feasible dose escalation for cancer phase I trialsStatistics & Probability Letters, 1998
- IMPROVED DESIGNS FOR DOSE ESCALATION STUDIES USING PHARMACOKINETIC MEASUREMENTSStatistics in Medicine, 1996
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995
- Toxicity in sequential dose-response experimentsSequential Analysis, 1995
- The continual reassessment method in cancer phase i clinical trials: A simulation studyStatistics in Medicine, 1993
- Quest: A Bayesian adaptive psychometric methodPerception & Psychophysics, 1983
- Selection of Dose Levels for Estimating a Percentage Point of a Logistic Quantal Response CurveJournal of the Royal Statistical Society Series C: Applied Statistics, 1980
- Sequential Search of an Optimal Dosage, IJournal of the American Statistical Association, 1973
- Design of Experiment for BioassayJournal of the American Statistical Association, 1972
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961